Here are five observations:
1. Prior to the study, researchers knew IBS patients’ bowels had larger quantities of the substance histamine. However, they could not yet make the link with histamine and hypersensitivity.
2. The study enabled researchers to show how histamine impacted the pain receptor TRPV1. They found histamine interferes the histamine 1 receptor, which is located on nerves that contain TRPV1.
3. Through the study, researchers learned blocking the histamine 1 receptor stopped the sensitizing effect of histamine on TRPV1.
4. Based on these findings, researchers created a pilot study in IBA to learn about the effect of a substance that blocks the histamine 1 receptor on the nerve to ensure TRPV1 sensitivity doesn’t increase.
5. Researchers found the substance, ebastine, reduced abdominal pain in IBS patients. Researcher plan to conduct a follow-up study on the effect ebastine has on 200 IBS patients.
More articles on gastroenterology:
Exact Sciences expects to double number of Cologuard tests performed, EndoChoice projects $18.6M in Q4 revenue & more –7 GI/endoscopy company key notes
GI physician leader to know: Dr. Raymond DuBois of Medical University of South Carolina
NJ Chapter of American College of Surgeons names Dr. Michael Arvanitis president: 5 takeaways
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.